Close Menu

NEW YORK (GenomeWeb News) – Transgenomic believes that a new PCR technology that it recently licensed from the Dana-Farber Cancer Institute could have promise down the road as a screening tool to detect early-stage cancer in blood samples.

The technology, called coamplification at lower denaturation temperature PCR, or COLD-PCR, was developed by Mike Makrigiorgos' lab at Dana-Farber. It preferentially amplifies segments of DNA that contain mutations, and is thereby able to increase the sensitivity of downstream mutation-detection methods by a factor of 10 to 100.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.